Spaulding Clinical, a leading clinical research organization (CRO), is expanding its services to include ADME (absorption, distribution, metabolism, and excretion) clinical trials. This strategic addition further solidifies Spaulding Clinical’s commitment

Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia®, a once-daily novel, oral

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders

Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation

Biolinq Incorporated, a medtech company that is developing novel biosensing technologies, has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd., to commercialize a new generation of glucose monitoring products in Japan.

Freya Pharma Solutions, a pharmaceutical company dedicated to developing effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders announced today

Arcellx, Inc. a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced

RK Pharma Inc, a vertically integrated pharmaceutical company today announced the successful completion of the acquisition of VGYAAN Pharmaceuticals LLC. The acquisition of VGYAAN Pharmaceuticals aligns strongly with our growth strategy

Oliva Therapeutics, LLC, a healthcare company focused on product commercialization, sales, marketing, distribution, and promotion, announced today a long-term partnership with Rio Biopharmaceuticals, Inc., a subsidiary of the EMS S/A Pharma

Astellas Pharma Inc. and Cullgen Inc. today announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.